zoledronic acid has been researched along with Hormone-Dependent Neoplasms in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (70.83) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gamper, J; Grunt, TW; Gschwantler-Kaulich, D; Mairhofer, M; Singer, CF; Tan, Y; Weingartshofer, S | 1 |
| Atmaca, H; Degirmenci, M; Karaca, B; Kisim, A; Sanli, UA; Sezgin, C; Uslu, R; Uzunoglu, S; Varol, U | 1 |
| Cheng, J; Hong, Q; Jia, X; Lei, L; Li, D; Li, J; Liu, G; Mo, M; Shao, Z; Shen, Z; Wang, Y | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Gupta, NP; Nayyar, R; Sharma, N | 1 |
| Yuasa, T | 1 |
| Abrahamsson, PA; Miller, K; Saad, F | 1 |
| Bossi, A; Chauchereau, A; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Laplanche, A; Loriot, Y; Massard, C; Rajpar, S; Tournay, E | 1 |
| Fox, KR | 1 |
| Culver, KW; Diener, M; Guo, A; Namjoshi, M; Parikh, K; Wu, EQ; Xie, J; Yu, AP | 1 |
| Aft, RL; Naughton, M; Trinkaus, K; Weilbaecher, K | 1 |
| Chen, B; Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ | 1 |
| Saad, F | 1 |
| Bankhead, C | 1 |
| Berry, S; Winquist, E | 1 |
| Arena, G; Bertelli, G; Botto, A; Colantonio, I; Fea, E; Garrone, O; Giubergia, S; Heouaine, A; Merlano, M; Occelli, M | 1 |
| Antràs, L; Daskivich, T; Duh, MS; Evan, C; Nakabayashi, M; Neary, MP; Oh, WK; Proctor, K; Smith, M; Tormey, LK | 1 |
| Altieri, V; Autorino, R; Benincasa, G; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M; Morelli, E; Napodano, G; Russo, A | 1 |
| Bertelli, G; Jones, RM; Leonard, RC; Lewis, PD; Morgan, C; Thomas, GA | 1 |
| Buccheri, S; Caccamo, N; Cicero, G; D'Asaro, M; Dieli, F; Eberl, M; Fulfaro, F; Gebbia, N; Hayday, AC; Meraviglia, S; Roberts, A; Salerno, A; Vermijlen, D | 1 |
| Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S | 1 |
| Arlen, PM; Dahut, WL; Gulley, JL; Wu, S | 1 |
| Friese, K; Janni, W; Rack, B; Schindlbeck, C; Sommer, H; Strobl, B | 1 |
| Brufsky, AM | 1 |
2 review(s) available for zoledronic acid and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
Topics: Adult; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2009 |
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasm Staging; Neoplasms, Hormone-Dependent; Premenopause; Randomized Controlled Trials as Topic; Zoledronic Acid | 2007 |
8 trial(s) available for zoledronic acid and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Cost-Benefit Analysis; Denosumab; Diphosphonates; Disease Progression; Drug Costs; Health Care Costs; Humans; Imidazoles; Male; Markov Chains; Models, Economic; Multivariate Analysis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Sensitivity and Specificity; United States; Zoledronic Acid | 2011 |
Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Zoledronic Acid | 2012 |
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2002 |
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Humans; Imidazoles; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Pain Measurement; Palliative Care; Prednisone; Probability; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid | 2007 |
[Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Pain; Pilot Projects; Prognosis; Zoledronic Acid | 2008 |
14 other study(ies) available for zoledronic acid and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; DNA, Neoplasm; Estradiol; Female; Humans; Imidazoles; MCF-7 Cells; Neoplasms, Hormone-Dependent; Zoledronic Acid | 2017 |
Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2015 |
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Letrozole; MAP Kinase Signaling System; Mice; Mice, Nude; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Nitriles; Postmenopause; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Transcription, Genetic; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Diphosphonates; Docetaxel; Drug Synergism; Enzyme Activation; Fluorescent Dyes; Humans; Imidazoles; In Situ Nick-End Labeling; Male; MAP Kinase Kinase 1; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Taxoids; Time Factors; Zoledronic Acid | 2008 |
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Castration; Collagen Type I; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Peptides; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Bisphosphonates in prostate cancer: where are we and where should we go?
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Osteoporosis; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2003 |
Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Zoledronic Acid | 2003 |
Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Analysis of Variance; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2004 |
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Renal Insufficiency; Retrospective Studies; Risk Factors; Zoledronic Acid | 2007 |
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Minichromosome Maintenance Complex Component 2; Neoplasms, Hormone-Dependent; Nuclear Proteins; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Feasibility Studies; Humans; Imidazoles; Immunotherapy; Interleukin-2; Lymphocyte Activation; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Salvage Therapy; T-Lymphocytes; Treatment Outcome; Zoledronic Acid | 2007 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid | 2007 |
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Zoledronic Acid | 2007 |